2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159839
    Evategrel 2760609-74-1 98%
    Evategrel is a platelet aggregation inhibitor.
    Evategrel
  • HY-159895
    PAR4 antagonist 7 98%
    PAR4 antagonist 7 (Compound 20f) is selective PAR4 antagonist (IC50: 1.72 nM). PAR4 antagonist 7 inhibits PAR4 agonist-induced platelet aggregation. PAR4 antagonist 7 has good metabolic stability. PAR4 antagonist 7 does not show a bleeding tendency in mice.
    PAR4 antagonist 7
  • HY-159896
    PAR4 antagonist 8 98%
    PAR4 antagonist 8 (Compound 20f) is an effective, orally active, and selective PAR4 antagonist with an IC50 value of 15.32 nM. PAR4 antagonist 8 exhibits favorable pharmacokinetic properties. PAR4 antagonist 8 not only effectively inhibits human platelet aggregation induced by PAR4 agonists (IC50 = 6.39 nM) but also inhibits mouse platelet aggregation. PAR4 antagonist 8 can be used in antithrombotic research.
    PAR4 antagonist 8
  • HY-159952
    ALK5-IN-84 98%
    ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pKi value of 9.35 against hALK5. When administered via inhalation, ALK5-IN-84 exhibits significant ALK5 inhibitory activity. ALK5-IN-84 is promising for the development of inhaled ALK5 inhibitors.
    ALK5-IN-84
  • HY-160031
    GLP-1R agonist 19 2765065-09-4 98%
    GLP-1R agonist 19 (M3190) is a potent and selective GLP-1R agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity.
    GLP-1R agonist 19
  • HY-160076
    APJ receptor agonist 8 2049973-39-7 98%
    APJ receptor agonist 8 (compound 99) is an agonist of APJ receptor. APJ receptor agonist 8 increases the load independent cardiac contractility of isolated perfused rat hearts.
    APJ receptor agonist 8
  • HY-160209
    KIO-301 1643463-61-9 98%
    KIO-301 is a photoswitchable HCN channel blocker, and can be used as the vitreous “light switch” molecule that reactivates retinitis pigmentosa.
    KIO-301
  • HY-160292
    Enoltasosartan 159237-67-9 98%
    Enoltasosartan is an angiotensin II (AngII) receptor blocker.
    Enoltasosartan
  • HY-16056A
    Arbutamine hydrochloride 125251-66-3 98%
    Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
    Arbutamine hydrochloride
  • HY-160587
    Antiangiogenic agent 5 2095397-52-5 98%
    Antiangiogenic agent 5 (compound 17) has anti-angiogenic activity. Antiangiogenic agent 5 show inhibition to SRPK1, with IC50 of 1.3 nM.
    Antiangiogenic agent 5
  • HY-160616
    LPA5 antagonist 3 1664336-44-0 98%
    LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis.
    LPA5 antagonist 3
  • HY-160637
    Lp-PLA2-IN-17 1818842-74-8 98%
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2.
    Lp-PLA2-IN-17
  • HY-160664
    TP receptor antagonist-2 1448452-22-9 98%
    TP receptor antagonist-2 (example 7n) is a thromboxane A2 receptor (TP receptor) antagonist, with IC50 values of 5.64 and 5.27 μM for TPα and TPβ, respectively. TP receptor antagonist-2 inhibits platelet aggregation.
    TP receptor antagonist-2
  • HY-160676
    sEH-IN-1 1061377-99-8 98%
    sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on.
    sEH-IN-1
  • HY-160980
    Sornidipine 95105-77-4 98%
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.
    Sornidipine
  • HY-161290
    PDE5-IN-12 98%
    PDE5-IN-12 (compound 4h) is a potent phosphodiesterase-5 (PDE-5) inhibitor with an IC50 of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line.
    PDE5-IN-12
  • HY-161401
    PAR4 antagonist 2 98%
    PAR4 antagonist 2 (Compound 31) is a protease activated receptor 4 (PAR4) antagonist, with IC50 values of 95 nM and 367 nM for human PAR4 and mouse PAR4. PAR4 antagonist 2 is active against PAR4 activation by the native protease thrombin cleavage but not the synthetic PAR4 agonist peptide AYPGKF.
    PAR4 antagonist 2
  • HY-161572
    Nav1.8-IN-13 2785391-79-7 98%
    Nav1.8-IN-13 (compound 16) is a Nav1.8 inhibitor (pIC50=7.9).
    Nav1.8-IN-13
  • HY-161608
    Myosin modulator 1 3034189-56-2 98%
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats.
    Myosin modulator 1
  • HY-161609
    Myosin modulator 2 3034189-87-9 98%
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats.
    Myosin modulator 2
Cat. No. Product Name / Synonyms Application Reactivity